855 reports of this reaction
1.5% of all LAMIVUDINE reports
#16 most reported adverse reaction
EXPOSURE DURING PREGNANCY is the #16 most commonly reported adverse reaction for LAMIVUDINE, manufactured by ViiV Healthcare Company. There are 855 FDA adverse event reports linking LAMIVUDINE to EXPOSURE DURING PREGNANCY. This represents approximately 1.5% of all 57,073 adverse event reports for this drug.
Patients taking LAMIVUDINE who experience exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for LAMIVUDINE, but still significant enough to appear in the safety profile.
In addition to exposure during pregnancy, the following adverse reactions have been reported for LAMIVUDINE:
The following drugs have also been linked to exposure during pregnancy in FDA adverse event reports:
EXPOSURE DURING PREGNANCY has been reported as an adverse event in 855 FDA reports for LAMIVUDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EXPOSURE DURING PREGNANCY accounts for approximately 1.5% of all adverse event reports for LAMIVUDINE, making it a notable side effect.
If you experience exposure during pregnancy while taking LAMIVUDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.